Bradykinin B1 antagonist R-954 Cancer Bradykinin Ehrlich ascitic tumor a b s t r a c t
Introduction
Bradykinin is a peptide with several biological activities including vasodilation, vascular permeability, and pain (reviewed in [6, 23] ). Bradykinin was shown to play a role in various pathological states, including inflammation [46, 47, 54] , shock [4, 11] , hypertension [32, 35] , and airway diseases [43] . Other studies have reported that bradykinin stimulated angiogenesis in vivo [21] , increased vascular permeability in ascitic tumors and promoted tumor growth [28, 33, 58] . The first evidence for the presence of bradykinin receptors in lung cancer was presented in 1989 by Woll and Rozengurt [56] . Many reports further related the presence of these receptors in a wide variety of cancers [1, 7, 48] . Bradykinin and desArg 9 -BK could act as a growth factor for a number of tumor types. Furthermore several tumor cells can generate bradykinin and express its receptors which in turn favor an autocrine stimulation of tumor growth. Bradykinin could not only stimulate tumor growth directly but also stimulate their neovascularization by stimulating the release of vascular endothelial growth factor [22] , acting as a pluripotent agent for stimulating tumor growth and invasion [57] .
Biological actions of kinins are mediated by two G proteincoupled receptors, designated B l and B2 [6, 29, 30, 45] . B 2 receptors are constitutively expressed in a wide variety of tissues whereas B l receptors are not normally present in most tissues, but their expression is rapidly induced in various inflammatory conditions. It has been suggested that the B 1 receptor might represent an attractive target in prostate carcinoma [2, 52] . Their results showed that there is a cross-talk between the two receptor subtypes in the proliferation of PC-3 cells. It appears that both BK and desArg 9 -BK can induce the activation of ERK and Akt pathways and PC-3 proliferation through the B 1 receptors. Surprisingly, inhibition of either receptors was sufficient to block kinin-induced ERK activation and cell proliferation. Another study supported more clearly the participation of the B 1 receptors in prostate cancer. This group found that the expression of these receptors is restricted to tumorous prostate tissues whereas the B 2 appeared more widely expressed in normal and diseased prostate [52] .
In brief bradykinin antagonists are under investigation as new antitumoral drugs and the B 1 receptor appears to be a potential target for adjunctive therapy of hormone-refractory prostate cancers. is the aim of several investigators [50] . In search of more potent and more selective bradykinin antagonists as potential anticancer agents, the effects of R-954 in mouse and rat models of Ehrlich tumor were evaluated.
Methods

Animals
All experiments were performed with male Balb/C mice (20-25 g) or male Wistar rats (150-200 g) obtained from our own animal facility. Animals were maintained in a room with controlled temperature 22 ± 2 • C for 12 h light/dark cycle, with free access to food and water. Animals were killed in a chamber with saturated CO 2 atmosphere to avoid hemorrhage in the peritoneal cavity. Animal care, research and animal sacrifice protocols were in accordance with the principles and guidelines adopted by the Brazilian College of Animal Experimentation (COBEA), were approved by the Biomedical Science Institute/UFRJ Ethical Committee for Animal Research, and received the protocol number ICBDFBC-015.
Treatment regimen
The bradykinin B 1 receptor antagonist R-954 (Ac-Orn-[Oic 2 , aMe Phe 5 , D-b Nal 7 , Ile 8 ] desArg 9 bradykinin) [36] was dissolved in sterile phosphate buffer saline (PBS) and administered subcutaneously at the dose of 2 mg/kg in a final volume of 0.1 ml per animal. Vincristine sulfate (Sigma Chem., St Louis, MO, USA) was used at the optimal concentration of 0.5 mg/kg for comparison purpose. The control group was given the vehicle (PBS). Mice and rats were given R-954 or vehicle every 24 h after inoculation of Ehrlich ascitic tumor cells until the end of experiment.
Ehrlich tumor
Ehrlich ascitic tumor (EAT) cells derived from a spontaneous murine mammary adenocarcinoma, were maintained in the ascitic form by sequential passages in Balb/C mice by means of weekly i.p. transplantations of 5 × 10 5 tumor cells. For the experiments on ascitic tumor, mice were given an i.p. inoculation of 5 × 10 5 tumor cells in 0.5 ml and were sacrificed 10 days after. Samples of blood, bone marrow lavage and ascitic fluid were colleted for several measurements as described. For the series of experiments on rat solid tumor, 5 × 10 5 tumor cells were injected in a volume of 0.1 ml in the footpad of rats and the contralateral paw was administered the vehicle [19] . Every 24 h and until the 7th day, the paw edema was measured by pletismography as described in [16] .
Total cell counts
Bone marrow cells were obtained by flushing the femoral cavity with 1 ml of PBS. A blood aliquot was collected for cell count. The ascitic fluid collected was centrifuged at 170 × g for 10 min at 4 • C. The supernatant was recovered for prostaglandin E 2 , TNF␣, protein and nitric oxide measurements. Aliquots from ascitic cell suspension, bone marrow cells, and blood were diluted 1:20 in Turk solution (20% acetic acid containing 0.5% Trypan Blue) for total cell count in a Newbauer chamber.
Total protein, PGE 2 , and TNF˛quantifications
Protein concentration was determined by the BCA method (BCA TM Protein Assay Kit, Pierce, IL, USA). The concentration of PGE 2 was determined with an EIA commercial kit (Cayman Chemical Co., MI, USA) according to the method of [42] . Briefly, dilutions of the supernatants were incubated with the conjugated eicosanoidacetylcholinesterase and the specific antiserum in 96-well plates pre-coated with anti-rabbit immunoglobulin G antibodies. After an overnight incubation at 4 • C, the plates were washed and the enzyme substrate (Elmman's reagent) was added and incubated for 60-120 min at 25 • C. The optical density of the samples was determined at 412 nm in a microplate reader, and the concentration of PGE 2 was calculated from a standard curve. TNF␣ activity in the ascitic fluid was determined by bioassay using L929 cells based on the method described by Flick and Gliford [17] .
Quantification of nitric oxide (NO) production
To evaluate NO production, the nitrate concentration in the ascitic fluid was measured through conversion of nitrate into nitrite [44] followed by the Griess reaction [20] . Briefly, equal volumes of ascitic fluid and Griess reagent (1% sulphanilamide, 0.1% naphthylethylene diamine dihydrochloride, 10% phosphoric acid) were incubated for 10 min at room temperature. The absorbance was measured at 540 nm using a microplate reader, and the nitrite concentration was calculated using a standard curve of sodium nitrite.
Statistical analysis
All experimental groups were composed by 6-8 animals. The results are presented as the mean ± S.D. Statistical significance between groups was determined by an analysis of variance ANOVA followed by the Bonferroni's test. Significant levels were defined as the P value being less than 0.05.
Results
Effect of R954 on Ehrlich ascitic tumor (EAT) volume, animal weight and survival
Intraperitoneal injection of EAT cells resulted in a marked ascitic liquid accumulation in mice. Maximal volume peaked the 10th day after the inoculation, after which no significant increase in volume was observed. After this period an intense hemorrhage was observed in the peritoneal cavity. In view of these initial observations, all experiments were performed on the 10th day after tumor inoculation. Mice treatment with the B 1 receptor antagonist R-954 (2 mg/kg, s.c.) for 10 days caused a significant reduction of ascitic fluid volume collected from the peritoneal cavity. The inhibitory effect was significant after the 9th day of treatment and persisted until the end of the experiment. Maximal inhibitory effect was observed the 9th (62.7% reduction) and 10th days (63.7% reduction) of treatment and declined slightly towards the end of the experiments (Fig. 1A) .
Daily treatment with R-954 inhibited the weight gain of EATinoculated mice as compared to untreated mice and the maximal inhibitory effect was obtained the 9th and 10th days (31% and 30.5% reduction, respectively, Fig. 1B ). When mouse survival was evaluated, it was noted that the first animal died on the 9th day in EAT-inoculated group of mice. At the 10th day a 20% death toll was noted, and only 50% of the animals were alive on the 15th day. In the R-954-treated group of mice, only one animal died during the experimental period and this death occurred only after 14 days of consecutive treatment (Fig. 1C) .
Effect of R-954 on blood, ascitic lavage, and bone marrow cell numbers
On the 10th day after EAT cell inoculation into mice, a 12.6-fold increase of total blood cell count was observed (0.5 ± 0.2 × 10 7 cells in control group vs. 6.3 ± 2.1 × 10 7 cells in EAT-inoculated 5 Ehrlich ascitic tumor cells. Twenty four hours after EAT inoculation and during the subsequent days, mice were treated with vincristine (0.5 mg/kg, i.p.) or R-954 (2 mg/kg, s.c.). In (A) ascitic fluid was collected and volume measurements were performed as described on methods section; in (B) mice were weighed; in (C) the number of animals that were alive were counted every day. Statistical significance was calculated by repetitive ANOVA followed by Bonferroni's test (n = 6-8). *P < 0.05 vincristine or R-954-treated mice compared with the vehicle-treated group. mice). This effect was accompanied by a proportional increase in total bone marrow cell count (0.12 ± 0.02 × 10 7 cells in control group vs. 1.3 ± 0.02 × 10 7 cells in EAT-inoculated mice) and on cells from ascitic lavage (0.8 ± 0.3 × 10 7 cells in control group vs. 11.7 ± 1.1 × 10 7 cells in EAT-inoculated mice). Vincristine (0.5 mg/kg, i.p.) a well known carcinostatic agent used for comparison purpose reduced total blood cell counts by 55.5% . On the 10th day mice were sacrificed. Ascitic fluid was collected and total cell counts in the ascitic fluid, blood and bone marrow were performed as described in Section 2. Statistical significance was calculated by ANOVA followed by Bonferroni's test (n = 6-8).
# P < 0.05 when comparing vehicle-treated mice with naïve group and *P < 0.05 when comparing vincristine or R-954-treated mice with vehicle-treated group.
EAT cells with B 1 antagonist R-954 reduced total blood, bone marrow, and ascitic cell counts to values similar to vincristine-treated mice (3.2 ± 0.9; 0.5 ± 0.1; 4.8 ± 1.1 × 10 7 cells, respectively) (Fig. 2) .
Effect of R-954 on inflammatory mediator production
In order to evaluate inflammatory mediator release after EAT inoculation, mice were sacrificed on the 10th day after tumor cell injection. Peritoneal ascitic fluid was collected and total protein, nitric oxide, PGE 2 , and TNF␣ were measured. In mice inoculated with EAT cells, marked increases of the total proteins (from 13.8 ± 3.1 to 493.5 ± 33.8 mg/ml), nitric oxide (from 2.8 ± 3.3 to 76.9 ± 12.7 M), PGE 2 (from 28.4 ± 5.9 to 344.9 ± 45.8 pg/ml), and TNF␣ (from 31.7 ± 9.9 to 792.3 ± 113.4 U/ml) were noted when compared to the levels in the fluids of non-inoculated animals. Treatment of mice with R-954 reduced significantly the total protein extravasation (57.3%) as well as the production of nitric oxide (56%), PGE 2 (82%) and TNF␣ (85.7%). The antitumoral drug vincristine also significantly reduced by 92% the protein extravasation, by 84.5% nitric oxide, by 94.7% PGE 2 , and by 92.2% TNF␣ levels ( Table 1) .
Effect of R-954 on solid Ehrlich tumor in rat paw
When Ehrlich cells are inoculated intraperitoneally, the tumor process develops in an ascitic form but when the cells are inoculated subcutaneously, the tumor develops in a solid form. The solid form was also used to study antitumoral activity of R-954. In the present study, the intraplantar injection of 10 5 EAT cells in rats induced a tumor and a progressive increase of paw edema which reached a plateau on the 6th day after inoculation. After this time period, the paw edema did not increase further and necrotizing tissues developed at the inoculation site (data not shown). Treatment of rats with the B1 antagonist R-954 for 6 days significantly reduced (51.4%) the edema formation. When the treatment was prolonged for more than 6 days, animals did not develop necrotizing tissues Table 1 Effect of the B1 receptor antagonist R-954 treatment on protein extravasation, nitric oxide (NO), PGE2 and tumor necrosis factor (TNF␣) production in peritoneal ascitic fluid. (data not shown). Similar results were obtained with vincristine (52.5% reduction) used as positive control (Fig. 3) .
Discussion
This study presents for the first time the antitumoral activity of a new bradykinin B 1 receptor antagonist (R-954) on ascitic and solid tumors induced by Ehrlich cell inoculation in mice and rats. The results showed that the inoculation of Ehrlich tumor cells in mice induced the formation of large ascitic tumors which were maximal after 9-10 days. The size of the tumor did not increase further in the following days. Although only one animal died on the 9th day after the inoculation, the death toll increased to 20% the following day and to 50% the 15th day. The treatment of Ehrlich tumor-bearing mice with R-954 during 10 days after tumor inoculation resulted in a significant reduction of ascitic volume which clearly suggested that the B 1 receptors was involved in the growth of this invasive tumor. At the effective doses used, compound R-954 showed no signs of general toxicity; the mouse weight gain was normal and internal organs did not show abnormalities (data not shown). In the group of animals which was given R-954 only one animal died during the full experimental period (after 15 days of treatment). This is in sharp contrast to the effects of the standard anti-cancer drugs vincristine used for comparison. At the doses of vincristine used to obtain the reported tumor inhibition, the mice were sick and did not gain weight.
Ehrlich tumor has been used as a transplantable tumor model to investigate the antineoplastic effects of several pharmacological agents. Following the intraperitoneal inoculation of Ehrlich tumor cells, the ascitic volume and number of tumor cells were shown to increase progressively [55] . Ascitis in the peritoneal cavity is the result of tumor-induced inflammation as shown by peritoneal vascular permeability increase and release of several inflammatory mediators [14, 15] . The exact mechanisms of the inhibitory effect of R-954 are still unknown but unpublished results showed that this compound did not have cytotoxic activities against up to 40 types of cancer cells. Its selective inhibitory action on tumor growth Fig. 3 . Effect of R-954 on rat paw solid Ehrlich tumor. Rats were given an intraplantar injection of 5 × 10 5 Ehrlich ascitic tumor cells. Every 24 h after inoculation rats were treated with vincristine (0.5 mg/kg, i.p.) or R-954 (2 mg/kg, s.c.) and paw edema was measured. Statistical significance was calculated by repetitive ANOVA followed by Bonferroni's test (n = 6-8). *P < 0.05 when comparing vincristine or R-954-treated rats with vehicle-treated group.
was suggested to be due to the inhibition of angiogenesis elicited by inflammatory mediators such as bradykinin and others formed during the development of the tumor. In support of this hypothesis, bradykinin B 1 antagonists were previously shown to have antiangiogenic activities [21] . The inhibitory effect of R-954 on the tumor growth could also be due to its inhibitory effect on the vascular permeability and protein leakage as demonstrated previously by our group [27] .
Experimental evidence confirms the presence of bradykinin B 1 and B 2 receptors in cancer tissues. Cervical cancer tissue displayed higher expression of both B 1 and B 2 receptors than did normal cervical tissue and the levels normalized following brachytherapy [37] . Prostate cancer tissue was found to express increased levels of B 1 receptors compared with normal prostate tissue [52] . Based on these findings several B 1 antagonists have been proposed for the treatment of various cancers, particularly lung and prostate cancers [48] . The BK antagonist CU-201 was shown to induce apoptosis and growth inhibition in various lung cancer and cancer cell lines [8, 9] . It was found to be a very potent stimulus for apoptosis in cultured SCLC, and it inhibited tumor growth of SCLC in athymic nude mice [9] . Other antagonists were also shown to inhibit the growth of prostate cancer in nude mice [49] . The Stewart group have developed a series of B 1 antagonists and the lead compound, BKM-570, was a very potent inhibitor of tumor growth in several types of cancers in nude mouse xenografts. This impressive activity in vivo is likely related to its potent inhibition of angiogenesis and matrix metalloproteases as well as to stimulation of apoptosis in addition to its direct inhibition of cell growth. The numerous activities in these compounds could provide a highly effective combination therapy and have potential for drug development [51] .
Our results also showed that the development of the tumor in mice was associated with a large increase (up to 12-fold) of blood cells, ascitic lavage cells and bone marrow cells. These effects were reduced by 60-77% following treatment of the mice with vincristine. R-954 produced a similar reduction of total cell numbers in bone marrow, blood, and ascitic fluid of EAT inoculated mice.
The observation that Ehrlich tumor is able to grow in almost all mice strains suggests that the recognition and immune responses to this tumor are independent of MHC [10] . It is an indication that the control of Ehrlich tumor growth is rather related to innate immunity, specially the inflammatory response. Our results are in agreement with those of Bergamini-Santos et al. [5] who demonstrated the importance of neutrophilic inflammatory response in Ehrlich tumor growth progression. It appeared that the initial inhibition caused by R-954 at the beginning of tumor progression reduced the neutrophil influx, thereby inhibiting the migration of other cell types.
Our results also showed that the peritoneal fluid of the mice which were inoculated with EAT cells showed a large increase of total protein, NO, PGE 2 and TNF␣ contents. The bradykinin B 1 receptor antagonist reduced protein, NO, PGE 2 , and TNF␣ levels in the peritoneal fluid of EAT inoculated mice by 56-86%. Vincristine produced a similar but larger inhibitory effect on the content of proteins, NO, PGE 2 and TNF␣ in the mouse peritoneal fluid. The leukocyte activation and migration induced by Ehrlich tumor cell inoculation, and cell activation are elements of host defense against tumor development. In this situation, an inverse relation-ship between macrophage spreading and Ehrlich tumor growth was already described [38, 39] . Similarly, the production of nitrogen intermediates such as NO has already been linked to the cytotoxic capabilities of host macrophages (among others) against tumor cells [24, 25] . Macrophage NO production, in this respect, is known to involve the cytokine network [25] . Bradykinin was shown to have inflammatory effects such as the activation of nuclear factor kappa B and the release of inflammatory cytokines (interleukin-1␤, TNF␣), chemokines, and prostaglandins [13, 40, 53] by acting on the inducible bradykinin B1 receptor. The fact that the bradykinin B 1 receptor gene is regulated by a promoter region with binding sites for transcription factors such as activator protein-1 and nuclear factor kappa B, which are both up-regulated during inflammation [29] , and that interleukin-1␤, TNF␣ and activation of mitogen-activated protein kinase are involved in the up-regulation of the bradykinin B 1 receptor [31] can explain the present results.
The results of the final set of experiments showed that the inoculation of EAT cells in the rat paw produced a solid tumor which peaked in size 6 days following the inoculation. In the subsequent days, there was a necrotizing tissue formation at the site of the tumor. The treatment with R-954 as well as with vincristine significantly reduced the paw edema and completely prevented the necrosis during the 15 days of the experimental protocol. These results clearly showed that the inhibition of bradykinin B 1 receptor could block one of the mechanisms responsible for tumor growth in this rat model almost as well as vincristine, a potent well known antineoplasic agent which blocks cell replication.
The exact signaling pathways involved in B 1 receptor-mediated tumor growth are not fully known. The binding of an agonist to B 1 receptors on target cells activates the heterotrimeric Gq proteins. It has been demonstrated that BK-induced activation of Gq subunits promotes the growth of tumor cells via phosphorylation of EGFR and ERK [3] . Other groups have reported that B 1 receptors activated the mitogenic ERK pathway and induced prostate cancer cell growth. The exact signal transduction pathway(s) used in the activation of ERK in tumor cells remains unclear. The antagonism of B 1 receptors was shown to attenuate prostate cancer cell growth and may be considered as an effective option for prostate cancer treatment.
Based on experimental evidence from ours and other laboratories, various hypotheses could be presented. First, B 1 receptors may regulate cell migration via activation of heterotrimeric G proteins [18, 34] . Meigs et al. [34] reported that activated G proteins inhibit cadherin functions such as cell adhesion and that the expression of constitutively active G proteins promoted breast cancer cell migration in a wound healing assay. Second, B 1 receptors can induce cell migration via ␤-arrestin proteins which are recruited to the plasma membrane to participate in many G protein-coupled receptorregulated signal transduction events [41] . Finally, B 1 receptors could regulate cancer cell movement via activation of matrix metalloproteinases, which promote degradation of the extracellular matrix, an early event in cell migration and metastasis [12, 26] .
In summary, our results showed that a novel selective antagonist of the bradykinin B 1 receptor, R-954 strongly inhibited Ehrlich tumor growth and increased survival in rats and mice. The inhibitory effects were compared with that of vincristine and the mechanism of action is discussed. Since local tumor control characterized by total tumor regression (complete response) and growth delay (partial response) coupled with normal tissue toxicity (systemic toxicity) determine therapeutic efficacy of any treatment regimen, all therapeutic strategies need to be evaluated from both aspects. Many of the chemotherapeutic strategies using single or a combination of anticancer agents could show good local tumor control but the therapeutic efficacy is often compromised by tissue toxicity which reduced the cure i.e. the disease (tumor) free survival. The excellent antitumor efficacy and absence of toxicity of R-954 suggest that it might be the prototype of a novel antitumor drug.
